Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
1 Werkwijze binnen de kinderfysiotherapie hoofdstuk lezen eerste hoofdstuk lezen

2016 | OriginalPaper | Hoofdstuk

14 Perifeer-neurologische aandoeningen

D Neuromusculaire aandoeningen en metabole myopathieën

Auteurs : Aad Verrips, Marja Schoenmakers, Tim Takken

Gepubliceerd in: Kinderfysiotherapie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Neuromusculaire aandoeningen (spierziekten, waarvan de metabole myopathieën een onderdeel zijn) kunnen op elke leeftijd tot uiting komen. Een deel ervan zal zich al tijdens de kinderleeftijd manifesteren. Kinderen met deze aandoeningen kunnen zich presenteren met vertraagde (psycho)motorische ontwikkeling, die gepaard kan gaan met spierzwakte, hypotonie, hyperlaxiteit of verminderde inspanningstolerantie.
vorige hoofdstuk 14 Perifeer-neurologische aandoeningen
volgende hoofdstuk 15 Kinderoncologische aandoeningen
Literatuur
1.
Tol-de Jager MJ van, Groot IJ de, Schoenmakers MAGC, et al. Neuromusculaire aandoeningen. In: Becher J, Maathuis C, Hadders-Algra M, red. Kinderrevalidatie, 5e dr. Assen: Van Gorcum, in druk.
2.
Johnston HM. The floppy weak infant revisited. Brain Dev. 2003;25:155-8.
3.
Prasad AN, Prasad C. The floppy infant: contribution of genetic and metabolic disorders. Brain Dev. 2003;25:457-76.
4.
Heckmatt JZ, Leeman S, Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr. 1982;101:656-60.
5.
Scholten RR, Pillen S, Verrips A, et al. Quantitative ultrasonography of skeletal muscles in children: assessment of normal values. Muscle Nerve. 2003;27:693-8.
6.
Maurits NM, Beenakker EA, Schaik DE van, et al. Muscle ultrasound in children: normal values and application to neuromuscular disorders. Ultrasound Med Biol. 2004;30:1017-27.
7.
Pillen S, Scholten RR, Zwarts MJ, et al. Quantitative skeletal muscle ultrasonography in children with suspected neuromuscular disease. Muscle Nerve. 2003;27:699-705.
8.
Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophydetermining gene. Cell 1995;80:155-65.
9.
Talbot K, Davies KE. Spinal muscular atrophy. Semin Neurol. 2001;21:189-97.
10.
Dubowitz V. Muscle disorders in childhood, 2nd ed., Londen: Saunders, 1995. p. 325-70.
11.
Soler-Botija C, Ferrer I, Gich I, et al. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain. 2002;125(Pt 7):1624-34.
12.
Ravid S, Topper L, Eviatar L. Acute onset of infantile spinal muscular atrophy. Pediatr Neurol. 2001;24:371-2.
13.
Bürglen L, Amiel J, Viollet L, et al. Survival motor neuron gene deletion in the arthrogryposis multiplex congenita-spinal muscular atrophy association. J Clin Invest. 1996;98:1130-2.
14.
Gontard A von, Zerres K, Backes M, et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord. 2002;12:130-6.
15.
Bussaglia E, Clermont O, Tizzano E, et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet. 1995;11:335-7.
16.
Campbell L, Potter A, Ignatius J, et al. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997;61:40-50.
17.
Scheffer H, Cobben JM, Matthijs G, Wirth B. Best practice guidelines for molecular analysis in spinal muscular atrophy. Eur J Hum Genet. 2001;9:484-91.
18.
Wang CH, Finkel RS, Bertini ES, et al.; Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027-49.
19.
Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Arch Neurol. 1995;52:518-23.
20.
Bach JR, Niranjan V, Weaver B. Spinal muscular atrophy type 1: A noninvasive respiratory management approach. Chest. 2000;117:1100-5.
21.
Birch JG. Orthopedic management of neuromuscular disorders in children. Semin Pediatr Neurol. 1998;5:78-91.
22.
Tilton AH, Miller MD, Khoshoo V. Nutrition and swallowing in pediatric neuromuscular patients. Semin Pediatr Neurol. 1998;5:106-15.
23.
Deymeer F, Serdaroglu P, Parman Y, et al. Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude. Neurology. 2008;71:644-9.
24.
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443-52.
25.
Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol. 2012;72:9-17.
26.
Wadman RI, Bosboom WM, Pol WL van der, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2012;(4):CD006281.
27.
Wadman RI, Bosboom WM, Pol WL van der, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2012;(4):CD006282.
28.
Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68:979-84.
29.
McDonald CM. Peripheral neuropathies of childhood. Phys Med Rehabil Clin N Am. 2001;12:473-90.
30.
Bertorini T, Narayanaswami P, Rashed H. Charcot- Marie-Tooth disease (hereditary motor sensory neuropathies) and hereditary sensory and autonomic neuropathies. Neurologist. 2004;10:327-37.
31.
Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol. 2004;17:579-85.
32.
Verhamme C, Baas F. Van gen naar ziekte; de ziekte van Charcot-Marie-Tooth ofwel de hereditaire motorische en sensorische neuropathieën. Ned Tijdschr Geneeskd. 2005;149:1505-9.
33.
Ichikawa K, Nezu A. Hereditary neuropathy with liability to pressure palsies in childhood: report of a case and a brief review. Brain Dev. 2005;27:152-4.
34.
Pareyson D, Reilly MM, Schenone A, et al. CMT-TRIAAL; CMT-TRAUK Groups. Ascorbic acid in Charcot-Marie- Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10:320-8.
35.
Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654-67.
36.
Ryan MM. Guillain-Barre syndrome in childhood. J Paediatr Child Health. 2005;41:237-41.
37.
Riekhoff AG, Jadoul C, Mercelis R, et al. Childhood chronic inflammatory demyelinating polyneuroradiculopathy – three cases and a review of the literature. Eur J Paediatr Neurol. 2012;16:315-31.
38.
Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24:101-10.
39.
Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve. 2003;27:4-25.
40.
Harper CM. Congenital myasthenic syndromes. Semin Neurol. 2004;24:111-23.
41.
Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord. 2004;14:635-49.
42.
Muntoni F, Bushby K, Ommen G van. 128th ENMC international workshop on ‘Preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy. 22-24 October 2004, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:450-7.
43.
Muntoni F, Voit T. 133rd ENMC international workshop on congenital muscular dystrophy (IXth international CMD workshop) 21-23 January 2005, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:794-801.
44.
Cormand B, Pihko H, Bayes M, et al. Clinical and genetic distinction between Walker-Warburg syndrome and muscle-eye-brain disease. Neurology. 2001;56:1059-69.
45.
Wang CH, Bonnemann CG, Rutkowski A, et al.; International Standard of Care Committee for Congenital Muscular Dystrophy. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010;25:1559-81.
46.
Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet. 2005;42:673-85.
47.
Udd B, Meola G, Krahe R, et al. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromusc Disord. 2003;13:589-96.
48.
Campbell C, Sherlock R, Jacob P, Blayney M. Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics. 2004;113:811.6.
49.
Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve. 2005;32:1-18.
50.
Roig M, Balliu PR, Navarro C, et al. Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy. Pediatr Neurol. 1994;11:208-13.
51.
Johnson NE, Heatwole CR. Myotonic dystrophy: from bench to bedside. Semin Neurol. 2012;32:246-54.
52.
Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864-7.
53.
Logigian EL, Martens WB, Moxley RT IV, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74:1441-8.
54.
Foff EP, Mahadevan MS. Therapeutics development in myotonic dystrophy type 1. Muscle Nerve. 2011;44:160-9.
55.
Gospe SM Jr, Lazaro RP, Lava NS, et al. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. Neurology. 1989;39:1277-80.
56.
Bush A, Dubowitz V. Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromusc Disord. 1991;1:201-4.
57.
Minetti C, Bonilla E. Mosaic expression of dystrophin in carriers of Becker’s muscular dystrophy and the X-linked syndrome of myalgia and cramps. N Engl J Med. 1992;327:1100.
58.
Samaha FJ, Quinlan JG. Dystrophinopathies: clarification and complication. J Child Neurol. 1996;11:13-20.
59.
Beggs AH. Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation. 1997;95:2344-7.
60.
Grain L, Cortina-Borja M, Forfar C, et al. Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Neuromuscul Disord. 2001;11:186-91.
61.
Emery AEH. The muscular dystrophies. Lancet. 2002;359:687-95.
62.
Emery A, Muntoni F. Duchenne muscular dystrophy, 3rd ed. Oxford: Oxford University Press, 2003.
63.
Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:121-5.
64.
Bushby K, Finkel R, Birnkrant DJ, et al.; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93.
65.
Bushby K, Finkel R, Birnkrant DJ, et al.; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177-89.
66.
Jennekens FG, Visser M de, Wintzen AR, Wokke JH. Vooralsnog ziekte van Duchenne niet behandelen met prednison. Ned Tijdschr Geneeskd. 1996;140:1109-11.
67.
Vereniging Spierziekten Nederland. Protocol voor Duchenne en Becker spierdystrofie. Baarn: VSN, 1996. www.​vsn.​nl.
68.
Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.
69.
Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64:13-20.
70.
Beenakker EAC, Maurits NM, Fock JM, et al. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paedtric Neurol. 2005;9:387-93.
71.
Beenakker EA, Fock JM, Tol MJ van, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005;62:128-32.
72.
Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77:444-52.
73.
Deutekom JC van, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357:2677-86.
74.
Goemans NM, Tulinius M, Akker JT van den, et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med. 2011;364:1513-22.
75.
Bushby KM. Making sense of the limb-girdle muscular dystrophies. Brain. 1999;122(Pt 8):1403-20.
76.
Straub V, Bushby K. The childhood limb-girdle muscular dystrophies. Semin Pediatr Neurol. 2006;13:104-14.
77.
Tubridy N, Fontaine B, Eymard B. Congenital myopathies and congenital muscular dystrophies. Curr Opin Neurol. 2001;14:575-82.
78.
North KN. Clinical approach to the diagnosis of congenital myopathies. Semin Pediatr Neurol. 2011;18:216-20.
79.
Pierson CR, Tomczak K, Agrawal P, et al. X-linked myotubular and centronuclear myopathies. J Neuropathol Exp Neurol. 2005;64:555-64.
80.
Jungbluth H, Sewry C, Brown SC, et al. Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromuscul Disord. 2000;10:264-73.
81.
Jungbluth H, Zhou H, Hartley L, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology. 2005;65:1930-5.
82.
Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet. 2002;71:739-49.
83.
Wang CH, Dowling JJ, North K, et al. Consensus statement on standard of care for congenital myopathies. J Child Neurol. 2012;27:363-82.
84.
McArdle WD, Katch VL. Exercise physiology-energy, nutricion, and human performance. Philadelphia: Lea & Febiger, 1991.
85.
Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;114(5 Suppl):S35-43.
86.
Hout JM van den, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113:e448-57.
87.
Capelle CI van, Winkel LP, Hagemans ML, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord. 2008;18:447-52.
88.
Tarui S, Okuno G, Ikura Y, et al. Phosphofructokinase deficiency in skeletal muscle: a new type of glycogenosis. Biochem Biophys Res Commun. 1965;19:517-23.
89.
DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science. 1973;182:929-31.
90.
Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr. 1999;88:237-45.
91.
Tein I, De Vivo DC, Hale DE, et al. Short-chain L-3- hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol. 1991;30:415-9.
92.
Fishbein WN, Armbrustmacher VW, Griffin JL. Myoadenylate deaminase deficiency: a new disease of muscle. Science. 1978;200:545-8.
93.
Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc. 2005;37:2086-93.
94.
DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord. 2005;15:276-86.
95.
Fahy MJ, Hall JG. A retrospective study of pregnancy complications among 828 cases of arthrogryposis. Genet Couns. 1990;1:3-11.
96.
Hall JG, Reed SD, Driscoll EP. Amyoplasia: A common sporadic condition with congenital contractures. Am J Med Genet. 1983;15:571-90.
97.
Brück A. Über eine seltene Form von Erkrankung der Knochen und Gelenke. Dtsch Med Wochenschr. 1897;23:152-5.
98.
Sarwark JF, MacEwen GD, Scott CI Jr. Current concepts review: Amyoplasia (a common form of arthrogryposis). J Bone Joint Surg Am. 1990;72:465-9.
99.
Sells JM, Jaffe KM, Hall JG. Amyoplasia, the most common type of arthrogryposis: the potential for good outcome. Pediatrics. 1996;97:225-31.
100.
Schoenmakers MAGC, Verhage MJ, Tol-de Jager MJ van, Pruijs JEH. Arthrogryposis multiplex congenita; mutilpele congenitale contracturen. In: Meijhuizen-de Regt MJ, de Moor JMH, Mulders AHM, red. Kinderrevalidatie, 4e dr. Assen: Van Gorcum, 2009. p. 479-89.
101.
Hahn G. Arthrogryposis: pediatric review and habilitative aspects. Clin Orthop. 1985;194:104-14.
102.
Emery AE. X-linked muscular dystrophy with early contractures and cardiomyopathy (Emery-Dreifuss type). Clin Genet. 1987;32:360-7.
103.
Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol. 2000;48:170-80.
104.
Beenakker EAC, Hoeven JH van der, Fock JM, et al. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynometry. Neuromuscul Disord. 2001;11:441-6.
105.
Sloan C. Review of reliability and validity of myometry with children. Phys Occ Therap Ped. 2002;22:79-93.
106.
Mercuri E, Mayhew A, Muntoni F, et al. Towards harmonisation of outcome measures for DMD and SMA within Treat-NMD; Report of three expert workshops in 2007. Neuromuscul Disord. 2008;18:894-903.
107.
Beld WA van den, Sanden GAC van der, Sengers BCA, et al. Validity and reproducibility of a new diagnostic motor performance test in children with suspected myopathy. Dev Med Child Neurol. 2006;48:20-7.
108.
Beld WA van den, Sanden GAC van der, Janssen AJWM, et al. Comparison of 3 instruments to measure muscle strength in children: a prospective study. Eur J Paediatr Neurol. 2011;15:512-8.
109.
Bérard C, Payan C, Hodgkinson I, et al. A motor function measure scale for neuromuscular diseases. Construction and validity study. Neuromuscul Disord. 2005;15:463-70.
110.
McDonald CM, Widman LM, Walsh DD, et al. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil. 2005;86:802-8.
111.
Scott OM, Hyde SA, Goddard C, et al. Prevention of deformity in Duchenne muscular dystrophy. A prospective study of passive stretching and splintage. Physiotherapy. 1981;67:177-80.
112.
Scott OM, Hyde SA, Goddard C, et al. Effect of exercise in Duchenne muscular dystrophy. A controlled sixmonth feasibility study of the effects of two different regimes of exercises in children with Duchenne muscular dystrophy. Physiotherapy. 1981;67:174-6.
113.
Mazonne ES, Messina G, Vasco M, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009;19:458-61.
114.
Steffensen B, Hyde S, Lyager S, et al. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int. 2001;6:119-34.
115.
Steffensen B, Hyde S, Atterman J, et al. Reliability of the EK scale, a functional assessment of non-ambulatory persons with Duchenne dystrophy. Adv Physiother. 2002;4:37-47.
116.
Main M, Kairon H, Mercuri E, et al. The Hammersmith Functional Motor Scale for children with spinal muscular atrophy: a scale to test ability and motor progress in children with limited ambulation. Eur J Peadiatr Neurol. 2003;7:155-9.
117.
Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith Functional Motor Scale for spinal muscular atrophy in a multicenter study. Neuromuscul Disord. 2006;16:93-8.
118.
Krosschell KJ, Maczulski J, Crwaford TO, et al. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord. 2006:16; 417-26.
119.
O’Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693-7.
120.
Glanzman AM, Mazzone E, Main M, et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155-61.
121.
Vandervelde L, Bergh PY, Goemans N, et al. ACTI-VLIM: a rasch-built measure of activity limitations in children with neuromuscular disorders. Neuromuscul Disord. 2007;17:459-69.
122.
Vandervelde L, Bergh PY, Goemans N, et al. Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire. Neuromuscul Disord. 2009;19:99-103.
123.
Hyde SA, Fløytrup I, Glent S, et al. A randomized comparative study to two methods for controlling tendo achilees contracture in Duchenne muscular dystrophy. Neuromuscul Disord. 2000;10:257-63.
124.
Muntoni F, Bushby K, Manzur AY. Muscular dystrophy campaign funded workshop on management of scoliosis in Duchenne muscular dystrophy, 24 January 2005, London. Neuromuscul Disord. 2006;16:210-9.
125.
Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr. 2000;12:203-7.
126.
Perrin C, Unterbor JN, Ambrosio CD, et al. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve. 2004;29:5-27.
127.
Chatwin SL, Diggle RA, Jazzar RF, et al. Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness. Eur Respir J. 2003;21:502-8.
128.
Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008;131(Pt 11):2824-31.
129.
Yeldan I, Gurses HN, Yuksel H. Comparison study of chest physiotherapy home training programmes on respiratory functions in patients with muscular dystrophy. Clin Rehabil. 2008;22:741-8.
130.
Sockolov R, Irwin B, Dressendorfer RH, et al. Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil. 1997;58:195-201.
131.
Silva AC, Russo AK, Picarro IC, et al. Cardiorespiratory responses to exercise in patients with spinal muscular atrophy and limb-girdle dystrophy. Braz J Med Biol Res. 1987;20:565-8.
132.
Vignos PJ Jr, Watkins MP. The effect of exercise in muscular dystrophy. JAMA. 1987;197:843-8.
133.
Jansen M, Groot IJ de, Alfen N van, et al. Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study. BMC Pediatr. 2010;10:55.
134.
Sveen ML, Andersen SP, Ingelsrud LH, et al. Resistance training in patients with limb-girdle and Becker muscular dystrophies. Muscle Nerve. 2013;47:163-9.
135.
Kooi EL van der, Vogels OJ, Asseldonk RJ van, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:702-8.
136.
Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology. 2005;64:1064-6.
137.
Ansved T. Muscular dystrophies: Influence of physical conditioning on the disease evolution. Curr Opin Clin Nutr Metab Care. 2003;6:435-9.
138.
Haller RG, Bertocci LA. Exercise evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C, eds. Myology, 2nd ed. New York: McGraw-Hill, 1994. p. 807-21.
139.
Tarnopolsky M. Exercise testing as a diagnostic entity in mitochondrial myopathies. Mitochondrion. 2004;4:529-42.
140.
Vissing J, Haller RG. A diagnostic cycle test for McArdle’s disease. Ann Neurol. 2003;54:539-42.
141.
Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med. 2003;349:2503-9.
142.
Haller RG, Wyrick P, Cavender D, et al. Aerobic conditioning: An effective therapy in McArdle’s disease. Neurology. 1998;50:A369.
143.
Ollivier K, Hogrel JY, Gomez-Merino D, et al. Exercise tolerance and daily life in McArdle’s disease. Muscle Nerve. 2005;31:637-41.
144.
Quinlivan R, Vissing J, Hilton-Jones D, et al. Physical training for McArdle disease. Cochrane Database Syst Rev. 2011;(12):CD007931.
145.
Duncan GE, Perkins LA, Theriaque DW, et al. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. J Clin Endocrinol Metab. 2004;89:1733-8.
146.
Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Ann Neurol. 2001;49:672-6.
147.
Taivassalo T, Jensen TD, Kennaway N, et al. The spectrum of exercise tolerance in mitochondrial myopathies: A study of 40 patients. Brain. 2003;126:413-23.
148.
Taivassalo T, De Stefano N, Chen J, et al. Short-term aerobic training response in chronic myopathies. Muscle Nerv. 1999;22:1239-43.
149.
Phillips BA, Mastaglia FL. Exercise therapy in patients with myopathy. Curr Opin Neurol. 2000;13:547-52.
150.
Siciliano G, Manca ML, Renna M, et al. Effects of aerobic training on lactate and catecholaminergic exercise responses in mitochondrial myopathies. Neuromuscul Disord. 2000;10:40-5.
151.
Taivassalo T, Shoubridg EA, Chen J, et al. Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects. Ann Neurol. 2001;50:133-41.
152.
Taivassalo T, Fu K, Johns T, et al. Gene shifting: A novel therapy for mitochondrial myopathy. Hum Mol Genet. 1999;8:1047-52.
153.
Cejudo P, Bautista J, Montemayor T, et al. Exercise training in mitochondrial myopathy: A randomized controlled trial. Muscle Nerve. 2005;32:342-50.
154.
Schreuder L, Peters G, Nijhuis-van der Sanden R, Morava E. Aerobic exercise in children with oxidative phosphorylation defects. Neurol Int. 2010;2:e4.
155.
Coyle EF. Substrate utilization during exercise in active people. Am J Clin Nutr. 1995;61:S968-79.
156.
Orngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61:559-61.
157.
Orngreen MC, Norgaard MG, Sacchetti M, et al. Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Ann Neurol. 2004;56:279-83.
158.
Orngreen MC, Duno M, Ejstrup R, et al. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005;57:60-6.
159.
Takken T, Custers J, Visser G, et al. Prolonged exercise testing in two children with a mild multiple acyl- CoA-dehydrogenase deficiency. Nutr Metab (Lond). 2005;2:12.
Metagegevens
Titel
14 Perifeer-neurologische aandoeningen
Auteurs
Aad Verrips
Marja Schoenmakers
Tim Takken
Copyright
2016
Uitgeverij
Bohn Stafleu van Loghum
Boek
Kinderfysiotherapie

Print ISBN: 978-90-368-1591-8

Elektronisch ISBN: 978-90-368-1592-5

Copyright: 2016

DOI
https://doi.org/10.1007/978-90-368-1592-5_31